Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
Patience Odeniyide(Johns Hopkins University), Christine A. Pratilas(Johns Hopkins University)
Cited by 41
Related Papers
BRAF mutation predicts sensitivity to MEK inhibition
|Nature|2005|1.3k
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
|Proceedings of the National Academy of Sciences|2010|447
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
|Cancer Research|2014|310
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)
|Neuro-Oncology|2022|136
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
|Cancer Immunology Research|2013|120